Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Invested Capital (2016 - 2025)

Historic Invested Capital for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $3.3 billion.

  • Neurocrine Biosciences' Invested Capital rose 2561.69% to $3.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.3 billion, marking a year-over-year increase of 2561.69%. This contributed to the annual value of $3.3 billion for FY2025, which is 2561.69% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Invested Capital of $3.3 billion as of Q4 2025, which was up 2561.69% from $3.0 billion recorded in Q3 2025.
  • Neurocrine Biosciences' Invested Capital's 5-year high stood at $3.3 billion during Q4 2025, with a 5-year trough of $1.2 billion in Q1 2021.
  • Over the past 4 years, Neurocrine Biosciences' median Invested Capital value was $2.5 billion (recorded in 2024), while the average stood at $2.3 billion.
  • In the last 5 years, Neurocrine Biosciences' Invested Capital tumbled by 100.18% in 2021 and then soared by 4894.03% in 2024.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Invested Capital stood at $1.3 billion in 2021, then surged by 78.46% to $2.4 billion in 2023, then grew by 7.81% to $2.6 billion in 2024, then increased by 25.62% to $3.3 billion in 2025.
  • Its last three reported values are $3.3 billion in Q4 2025, $3.0 billion for Q3 2025, and $2.7 billion during Q2 2025.